~~<i id='CC4DC6AED0'><strike id='CC4DC6AED0'><tt id='CC4DC6AED0'><pre id='CC4DC6AED0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：knowledge 2025-10-02 02:34:59 - browse：42296

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Juul documents reveal insider tactics on political lobbying

explore

entertainment

Wikipedia

knowledge

focus

leisure time

MollyFerguson/STATThisweek,apreviewoftheTUDCAstudyinALSandthoughtsonhowitmightimpactAmylyxPharmaceut

WSS

Long Covid research funding gets a major boost from NIH

Copay coupons to count toward deductibles, after Biden court move

Study gives hint on South Asians’ higher risk of cardiovascular disease

Having children helps parents live longer, especially after age 80

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

fashion

explore

ChatGPT in medicine: STAT answers readers' burning questions

Francis Collins on trust in science and how Covid communications failed

In Memoriam: Notable people who died in 2023

AMAs digital advisors table RPM coding reform proposal, again

Drug repurposing or repositioning? The language matters

Ebola vaccine can save some who are already sick, per new study

Walensky prepares to leave CDC — and Congress — behind

Study gives hint on South Asians’ higher risk of cardiovascular disease

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

entertainment

Humana cuts profit projections as Medicare Advantage costs soar

FDA clears AI tool for detecting skin cancer

Bernie Sanders gets little from pharma CEOs on drug prices

Why Eli Lilly’s earnings didn’t quite live up to the hype

Resistance to opioid

Test for long Covid? Researchers find new clue in blood samples

Wikipedia

knowledge

focus

leisure time